ADT + enzalutamide in mHSPC … outcome of the ARCHES trial

Posted on December 20, 2018 by Sitemaster

Pfizer and Astellas have, this morning, announced that the addition of enzalutamide to standard androgen deprivation (ADT) has led to improved outcomes in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , , , , | 2 Comments »

New form of PSA test is 1,700 times more sensitive

Posted on June 3, 2010 by Sitemaster

Data just published in Nature Biotechnology suggests that a new type of PSA test developed by a company called Quanterix is 1,700 times more sensitive than older, standard PSA detection methods used in clinical laboratories. … READ MORE …

Filed under: Living with Prostate Cancer, Management, Risk | Tagged: , , , | 3 Comments »

  • Donate

  • Disclaimer

    News and information provided on this site should not be used for diagnosing or treating any health problem or disease.

    The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.

  • Hot Posts …

  • … and Archives